We hypothesized that IL-1β signaling is responsible for the increased IL-1β mRNA levels, as well as increased miR-146a expression observed on day 3 of Meth treatment; we further hypothesized that IL-1β-dependent induction of miR-146a would target key innate immune pathways via TRAF6 inhibition.